Lupus pathophysiology in adults
Lupus, specifically systemic lupus erythematosus (SLE), is a complex autoimmune disease characterized by the immune system’s aberrant attack on the body’s own tissues. In adults, the pathophysiology of lupus involves a multifaceted interplay of genetic, environmental, hormonal, and immunological factors that culminate in widespread inflammation and tissue damage.
At its core, lupus is driven by a loss of immune tolerance. Normally, the immune system distinguishes between self and non-self, mounting responses only against pathogens. However, in lupus, this tolerance is broken. Genetic predispositions—such as variations in immune regulatory genes—contribute to a heightened susceptibility. These genetic factors influence immune cell function, including those of B and T lymphocytes, leading to their abnormal activation.
A hallmark of lupus is the production of a plethora of autoantibodies, notably antinuclear antibodies (ANA) and anti-double-stranded DNA (anti-dsDNA) antibodies. The genesis of these autoantibodies involves disruption in B cell tolerance mechanisms. Under normal circumstances, autoreactive B cells are eliminated or rendered inactive, but in lupus, these mechanisms fail, allowing self-reactive B cells to proliferate and produce pathogenic autoantibodies.
These autoantibodies form immune complexes by binding to self-antigens, such as nuclear components released from dying cells. The formation of immune complexes is central to lupus pathogenesis. These complexes circulate and deposit in various tissues, including the kidneys, skin, joints, and the vascular endothelium. Their deposition triggers complement activation and the recruitment of inflammatory cells, leading to tissue inflammation and damage.
Complement activation plays a dual role: it facilitates the clearance of immune complexes but, when dysregulated, can exacerbate tissue injury. The classical pathway of complement activation is often involved initially, leading to the generation of inflammatory mediators like C3a and C5a, which attract neutrophils and monocytes to sites of immune complex deposition.
Cell death pathways, particularly apoptosis, are also implicated. In lupus, defective clearance of apoptotic cells results in the accumulation of nuclear debris. This debris serves as an antigen source for autoantibody production, perpetuating the cycle of immune activation. Additionally, environmental triggers such as UV light, infections, and certain drugs can induce apoptosis or modify self-antigens, exacerbating the autoimmune response.
Hormonal influences, especially estrogen, are believed to modulate immune responses, which partly explains the higher prevalence of lupus in women of reproductive age. Estrogen enhances B cell survival and autoantibody production, amplifying disease activity.
The clinical manifestations of lupus stem from this immune-mediated damage. Vascular inflammation (vasculitis) can cause ischemia, while immune complex deposits in organs lead to conditions like lupus nephritis, a severe manifestation affecting the kidneys. Skin rashes, joint pain, and neurological symptoms are also common, reflecting the widespread nature of immune attack.
In conclusion, lupus pathophysiology in adults is a dynamic and intricate process involving genetic predisposition, immune dysregulation, autoantibody production, immune complex deposition, complement activation, and environmental influences. Understanding these mechanisms is essential for developing targeted therapies to modulate immune responses and prevent tissue damage.